Botox Managed Care Coverage On The Rise Following Flat Quarter, Allergan Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan is pointing to positive managed care coverage for Botox as positive news in light of sequentially flat growth for the product
You may also be interested in...
Botox Sweating Indication Launch Will Focus On Formulary Reimbursement
Allergan's launch of Botox' excessive sweating indication will center on gaining formulary access
Allergan's Botox Will Target 1.3 Mil. Severe Primary Axillary Hyperhidrosis Patients
FDA clears Botox for the treatment of primary axillary hyperhidrosis that is inadequately managed with topical agents. An FDA Talk Paper states patients should be evaluated for other potential causes of the problem, such as hyperthyroidism, prior to treatment.
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.